Cyclovirobuxin D

Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells.[Pubmed: 24758922]

J Pharmacol Sci. 2014;125(1):74-82. Epub 2014 Apr 24.

Autophagy is a highly regulated and multi-step biological process that serves to remove damaged cytoplasmic components and organelles. It has been suggested that the activation of autophagy may be a promising therapeutic strategy for cancer treatment by triggering cell death.
METHODS AND RESULTS:
In this study, we reported that Cyclovirobuxine D (CVB-D), an alkaloid component in a traditional Chinese herb, could induce autophagy in the MCF-7 human breast cancer cell line. CVB-D inhibited the viability of MCF-7 cells in a concentration- and time-dependent manner. Activation of autophagy was characterized by transmission electron microscopy, monodansylcadaverine staining, and expression of autophagy marker microtubule-associated protein 1 light chain 3 (LC3). After CVB-D treatment, a clear accumulation of autophagosomes was observed accompanied with elevated LC3 fluorescent puncta. Western blot analysis revealed that CVB-D significantly promoted the conversion from LC3-I to LC3-II and the expression of autophagy-related protein 5 (ATG5), which are both essential for autophagosome formation. On the other hand, CVB-D-induced autophagy and decrease in cell viability could be blocked by 3-methyladenine, a well-established autophagy inhibitor. Moreover, CVB-D attenuated the phosphorylation of Akt and mTOR, two pivotal suppressors in autophagy pathways.
CONCLUSIONS:
These findings shed new light on the pharmacological actions and mechanism of CVB-D and may support the potential utility of autophagy inducers in cancer treatment.

Comparison of the vasorelaxant effects of cyclovirobuxine D and its derivatives in rat aorta rings[Reference: WebLink]

Chinese Journal of New Drugs, 2012, 21(3):240-5.

To compare the vasorelaxant effects of Cyclovirobuxine D (CVB-D) and its derivatives in isolated rat thoracic aorta rings.
METHODS AND RESULTS:
Effects of CVB-D and its derivatives at various concentrations (from 1×10 -5 to 6×10 -4 mol·L -1) on contraction of aorta rings induced by potassium chloride (KCl) or phenylephrine (PE) were evaluated. Effects of preincubation with CVB-D or CBV-D3 at 6×10 -4 mol·L -1 on KCl- or PE-induced contraction were assessed in the aorta rings. In KCl- or PE-precontracted aorta rings, CVB-D showed a concentration-dependent vasorelaxant effect, CVB-D1 showed a weak vessel relaxation effect, but CVB-D2 showed no effect at concentrations of 1×10 -5~6×10 -4 mol·L -1. CVB-D3 showed a stronger vesorelaxant effect than CVB-D in the rings precontracted by KCl or PE. Furthermore, both CVB-D and CVB-D3 exhibited stronger vasorelaxation effects in the aorta rings with intacted endothelium than in the aorta rings with denuded endothelium. Additionally, preincubation with both CVB-D and CVB-D3 inhibited KCl- or PE-induced contraction, and the inhibitive effect of CVB-D3 was stronger than CVB-D.
CONCLUSIONS:
CVB-D and CVB-D3 have similar vasorelaxant effect, but CVB-D3 owned a higher maximum effect than CVB-D.

Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction.[Pubmed: 21575690]

Fitoterapia. 2011 Sep;82(6):868-77.

The effect of Cyclovirobuxine D, an active ingredient from Buxus microphylla, was investigated in the potential prevention of cardiac dysfunction in rats with congestive heart failure.
METHODS AND RESULTS:
Heart failure was induced by left coronary artery occlusion and verified using echocardiography. Cyclovirobuxine D was administered for 30 days (0.5, 1.0 and 2.0mg/kg, ig) and mortality, cardiac function, hemodynamics, microcirculation, histology and ultrastructure assessments were observed.
CONCLUSIONS:
Results from the present study suggest that Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction and supports the potential for Cyclovirobuxine D as a new therapy for heart failure.

Experimental and theoretical investigation on the interaction between cyclovirobuxine D and human serum albumin.[Pubmed: 24691369]

Spectrochim Acta A Mol Biomol Spectrosc. 2014 Jul 15;128:552-8.

Cyclovirobuxine D is an active compound extracted from the plant Buxux microphylla, and widely available as medications; however, its abuse may casts potential detrimental effects on human health. By using multispectroscopic techniques and molecular modeling, the interaction of Cyclovirobuxine D with human serum albumin was investigated. The fluorescence results manifested that static type was the operative mechanism for the interaction with human serum albumin. The structural investigation of the complexed HSA through CD, three-dimensional, FT-IR and synchronous fluorescence shown the polypeptide chain of HSA partially destabilizing. Docking studies revealed the molecule to be bound in the subdomain IIA. Finally, we investigated the distance between the bound ligand and Trp-214 of human serum albumin.

Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment.[Pubmed: 26075032]

Oxid Med Cell Longev. 2015;2015:151972.

The clinical application of doxorubicin (DOX) is compromised by its cardiac toxic effect. Cyclovirobuxine D (CVB-D) is a steroid alkaloid extracted from a traditional Chinese medicine, Buxus microphylla.
METHODS AND RESULTS:
Our results showed that CVB-D pretreatment markedly attenuated DOX-induced cardiac contractile dysfunction and histological alterations. By using TUNEL assay and western blot analysis, we found that CVB-D pretreatment reduced DOX-induced apoptosis of myocardial cells and mitochondrial cytochrome c release to cytosol. CVB-D pretreatment ameliorated DOX-induced cardiac oxidative damage including lipid peroxidation and protein carbonylation and a decrease in the ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG). Moreover, CVB-D was found to prevent DOX-induced mitochondrial biogenesis impairment as evidenced by preservation of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and nuclear respiratory factor 1 (NRF1), as well as mitochondrial DNA copy number.
CONCLUSIONS:
These findings demonstrate that CVB-D protects against DOX-induced cardiomyopathy, at least in part, by suppression of oxidative damage and mitochondrial biogenesis impairment.

Ameliorated effects of cyclovirobuxine D on oxidative stress and energy metabolism in experimental cardiac injured rats induced by sympathetic overactivity in vivo[Pubmed: 25566659]

Zhong Yao Cai. 2014 Jul;37(7):1213-7.

To investigate the ameliorated effect of CVB-D on oxidative stress and energy metabolism in experimental cardiac injuried rats induced by sympathetic overactivity in vivo.
METHODS AND RESULTS:
SD rats were randomly divided into five groups as following: control group, model group, Vitamin E 150 mg/kg group, CVB-D low dose and high dose groups, respectively. The rat experimental cardiac injury model was established by exposed to norepinephrine (NE) 3 mg/kg by ip for 16 d. The drugs were administrated to rat for 16 d by ig. The body weight of rats were monitored during all of the experimental period. At the designing ending-time point the indexes were assayed as following: cardiac index, hydroxyproline, histopathologically examination, oxidative stress ( MDA, SOD, CAT, GSH-Px and T-AOC) and energy metabolism indicatricle ( Na+, K(+) -ATPase, and Ca2+, Mg(2+) -ATPase). After exposed with NE for 16 d, the rats of model group was appeared dysfunction of oxidative stress and energy metabolism such as decreasing body weight, increasing cardiac index and hydroxyproline in cardiac tissue, decreasing Na+, K(+) -ATPase and Ca(2+), Mg(2+) -ATPase activities, and deteriorating the oxidative stress. Treated with CVB-D could ameliorate all of the exacerbated indexes.
CONCLUSIONS:
CVB-D has protective effect against oxidative stress and energy metabolism in rats of experimental myocardial injury induced by sympathetic overactivity.